The efficacy of swicthing from sulfonyl urea to the combination therapy with mitiglinide and voglibose on diurnal variation on glycemic control and endothelial function in patients with type 2 diabetes
Not Applicable
- Conditions
- type 2 diabetes
- Registration Number
- JPRN-UMIN000015638
- Lead Sponsor
- Tokyo Medical and Dental University
- Brief Summary
The switching from SUs to mitiglinide/voglibose significantly improved the glucose variability and endothelial function.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Patients treated with alphaGIs or glinides or insulin. Patients with infection, malignancy, severe liver, renal dysfuction. Pregnant patients. Patients who are unable to be responsible for informed concent due to dementia or impaired consciousness. Patients with past history of intestinal obstruction. Patients who has stared a new regimen of treatment for diabetes within 3 month prior to the registration of this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The change in FMD, measured by B-mode ultrasound, after 12 weeks
- Secondary Outcome Measures
Name Time Method The change in diurnal glycemic control assessed by continuous glucose monitoring after 12 weeks The change in HbA1c after 12 weeks